PepGen (NASDAQ:PEPG) Coverage Initiated by Analysts at Guggenheim

Guggenheim started coverage on shares of PepGen (NASDAQ:PEPG) in a research report released on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $6.00 target price on the stock.

Separately, HC Wainwright reduced their target price on shares of PepGen from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, May 29th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, PepGen currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

PepGen Stock Performance

NASDAQ PEPG opened at $1.48 on Tuesday. The stock has a market capitalization of $48.54 million, a P/E ratio of -0.50 and a beta of 1.17. PepGen has a 52 week low of $0.88 and a 52 week high of $10.06. The stock has a fifty day moving average of $1.28 and a 200-day moving average of $1.49.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.15. Equities research analysts forecast that PepGen will post -2.73 earnings per share for the current fiscal year.

Institutional Trading of PepGen

A number of institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of PepGen in the 1st quarter valued at approximately $25,000. ADAR1 Capital Management LLC bought a new stake in PepGen in the first quarter valued at approximately $29,000. Rangeley Capital LLC increased its stake in PepGen by 133.3% in the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after purchasing an additional 20,000 shares in the last quarter. Marshall Wace LLP acquired a new stake in PepGen in the second quarter worth $44,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of PepGen during the second quarter worth $81,000. 58.01% of the stock is owned by institutional investors.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.